Version May 2024
| Drugs | Dosing | Comments |
| Cytarabine plus daunorubicin | Cytarabine: 100 to 200 mg/m2 daily as a continuous infusion for 7 days; Daunorubicin: 60 to 90 mg/m2 intravenous push on each of the first 3 days of treatment | "Standard 7+3" induction regimen resulting in approximately 60 to 80% remission rate and acceptable toxicity in patients under 60 years old |
| Cytarabine (HiDAC) plus daunorubicin | Cytarabine: 1 to 3 g/m2 twice daily for a total of 12 doses; Daunorubicin: 45 mg/m2 intravenous push for 3 days following cytarabine | Yields a 90% remission rate; however, substantial toxicity precludes post-remission therapy in a high proportion of patients |
| Cytarabine plus idarubicin | Cytarabine: 100 to 200 mg/m2 daily as a continuous infusion for 7 days; Idarubicin: 12 to 13 mg/m2 IV push on each of first 3 days of treatment | Has produced a greater remission rate (88 versus 70%) than cytarabine/daunorubicin in younger patients; appears superior to daunorubicin in patients with hyperleukocytosis; overall survival not clearly superior to "standard" regimen |
| CPX-351: Liposomal daunorubicin plus cytarabine in a fixed 5:1 molar ratio | Daunorubicin (44 mg/m2) and cytarabine (100 mg/m2) intravenously over 90 minutes on days 1, 3, and 5 | CPX-351 achieved superior rates of remission and survival with comparable toxicity, when compared with 7+3 in older patients with AML |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
